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Abstract
Pulmonary Hypertension (PH) is a cardiopulmonary disease estimated to affect between
20 million to 70 million individuals globally, with poor prognosis and inadequate
treatment. Recent studies show the orphan G Protein Coupled Receptor 75 (GPR75) is
upregulated in the pulmonary vessels of PH patients, especially in females. Therefore, we
hypothesized that Gpr75 knock down (Gpr75-/-) mice will be protected from developing
PH. To test our hypothesis, we challenged isolated intra-lobar pulmonary artery (IPA) from
wild-type (WT; N=40) and Gpr75-/- (N=19) mice with hypoxia to examine their hypoxic
vasoconstrictive (HPV) response, which is a physiological response of pulmonary
circulation to balance ventilation-to-perfusion ratio that becomes maladaptive in chronic
hypoxia leading to the development of PH. IPA of Gpr75-/- mice developed very little or
no HPV response as compared to the WT mice. Next, Gpr75-/- (N=8) as compared with
WT (N=18) kept in hypoxic (10% O2) conditions for 5-weeks developed less PH as
indicated by significantly less increase in right ventricular systolic pressure (RVSP) and
diastolic pressure (RVDP). Gpr75-/- mice also expressed less inflammatory gene (Ccl2,
Ccl5, Cxcl12, and Prom1) and gene encoding rho associated coiled-coil containing protein
kinase 2 (Rock2), which are often overexpressed in lungs and pulmonary arteries of PH
mice and patients, but expressed more genes that encode bone morphogenetic protein
receptor 1a (Bmpr1a) and myosin heavy chain 11 (Myh11), a smooth muscle specific
protein gene that is often reduced in lungs and pulmonary arteries of PH mice and patients.
Vascular reactivity of WT and Gpr75-/- mice was also examined by challenging isolated
intra-lobar pulmonary arteries with vasoconstricting agents such as potassium chloride
(KCl), thromboxane mimetic (U46619), cyclic nucleotide channel inhibitor (ZD7288), and

ix

endothelin-1 (ET-1). The Gpr75-/- as compared with wild-type pulmonary arteries
contracted less to all the contractile agents. Since GPR75 is a G-protein coupled receptor,
to determine second messengers that potentially contribute to regulating contractile
function of pulmonary arteries we measured cAMP and IP3 in lungs of wild-type and
Gpr75-/- mice. While we found no difference in the IP3 levels between the WT and Gpr75/-

groups, cAMP levels were significantly higher in Gpr75-/- compared to levels in WT

mice. These results suggest GPR75 plays a major role in the development of PH by
potentially attenuating cAMP-dependent signaling and concomitantly augmenting
pulmonary constriction in response to hypoxia.

x

1. BACKGROUND
1.1

Pulmonary Hypertension
Pulmonary hypertension (PH) is a progressive and deadly cardiopulmonary disease that

is estimated to affect between 20 million to 70 million individuals globally and has a 1-year
mortality rate of 46% (Schmitt & Stork, 2001). PH is defined as having a resting mean
pulmonary artery pressure (PAP) of ≥25mmHg, which is due to remodeling of pulmonary
arteries (PAs) via increased proliferation of apoptosis resistant pulmonary arterial smooth
muscle cells (PASMCs) which leads to pulmonary arterial narrowing and increased vascular
resistance (Nie et al., 2018; Remy-Jardin et al., 2021; Tello et al., 2021). PH is defined as mild
with a mean PAP of >25 mm Hg, moderate with a mean PAP is between 41-55 mm Hg, and
severe if it’s >55 mm Hg (Lumb & Slinger, 2015). To reach this diagnosis, patients first
undergo echocardiography to establish the probability of having PH, then right heart
catheterization follows for an accurate diagnosis (Augustine et al., 2018; Moreira et al., 2015)
There are five major classifications of PH as described by the World Health
Organization (WHO), determined by origin of the disease which are summarized in Table 1.
Group 1 corresponds to pulmonary arterial hypertension (PAH) which can develop due to
idiopathic causes, heritability of gene mutations, drugs or toxins, and is commonly associated
with connective tissue disease, HIV infection, portal hypertension, and congenital heart
disease. Group 2 is PH due to left heart disease, which can develop because of left ventricular
systolic dysfunction, left ventricular diastolic dysfunction, valvular disease, congenital
cardiomyopathies, and congenital or acquired pulmonary vein stenosis. Group 3, the one we
focus on in the following experiments, is PH due to lung diseases and/or hypoxia. This form
of PH can develop from chronic obstructive pulmonary disease, interstitial lung disease, sleep

apnea, alveolar hypoventilation syndromes, and chronic exposure to high altitudes and low
oxygen levels. Group 4 describes chronic thromboembolic pulmonary hypertension and other
pulmonary artery obstructions, which can be developed because of pulmonary artery
obstructions, angiosarcoma, intravascular tumors, arteritis, and congenital pulmonary artery
stenosis. Group 5 describes PH with unclear and/or multifactorial mechanisms, such as that
associated with hematological disorders such as anemia, systemic disorders such as
sarcoidosis, metabolic disorders, such as glycogen storage disease, Gaucher disease, or thyroid
disorders (Kovacs et al., 2018). My thesis focuses on Group 3 PH.
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The Five Groups of Pulmonary Hypertension
Group

Causes

Group 1: Pulmonary Arterial Hypertension

Idiopathic, genetics, drug/toxin exposure,
scleroderma, lupus, HIV, portal hypertension,
and congenital heart disease

Group 2: Left Heart Disease

Coronary artery disease, high blood pressure,
damage to the heart muscle, heart valve
disease, and age

Group 3: Lung Disease

Chronic obstructive pulmonary disease
(COPD), interstitial lung disease, hypoxia, and
sleep apnea

Group 4: Chronic Thromboembolic
Pulmonary Hypertension

Old blood clots within the lungs – creates
barriers for blood flow within pulmonary
arteries

Group 5: Pulmonary Hypertension
resulting from unclear mechanisms

Sarcoidosis, sickle cell anemia, chronic
hemolytic anemia, spleen removal, Gaucher
disease, and thyroid disease

Table 1. The five classifications of pulmonary hypertension and some of their known causes,
according to the World Health Organization.
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1.2 Treatments for Pulmonary Hypertension
There are no cures for PH, only treatments to alleviate the symptoms (Table 2), such
as calcium channel blockers (CCBs), endothelin receptor antagonists, phosphodiesterase-5
inhibitors, guanylate cyclase stimulators, prostacyclin analogues, and prostacyclin receptor
agonists, which is why research into more effective treatments for PH is so important (Pesto et
al., 2016). A summary of these drug classes with examples from each group is provided in
Table 2.
1.2.1 Calcium Channel Blockers
Dihydropyridine CCBs, such as Amlodipine, help to alleviate symptoms in patients
suffering from PH by acting on vascular smooth muscle to reduce vascular resistance and
reduce PAP. Not all PH patients respond well to CCBs, but those who do can elicit an acute
15% decrease in mean PAP and a 26% reduction in pulmonary vascular resistance (PVR) (Liu
et al., 2013). Studies have also shown that the responding patients treated long-term with the
highest tolerable dose of CCBs had a mortality of 6% after 5 years, compared to those
unresponsive to CCBs that had a 45% mortality rate after 5 years (Liu et al., 2013).
1.2.2 Endothelin Receptor Antagonists
For those patients who do not respond well to CCBs, there are other treatments
available, for example ET-1 antagonists, such as Ambrisentan. ET-1 is a peptide, that is
induced by hypoxia, shear stress, cytokines, and thrombin, and is primarily produced in the
vascular endothelium, as well as in PASMCs and lung fibroblasts (Ould Amer & HebertChatelain, 2018). There are two ET-1 receptors, ETAR, which is expressed primarily in the
large PAs, and ETBR, which predominates in the airway smooth muscle, alveolar walls, and

4

capillaries (Galie et al., 2004). ET-1-ETAR and ET-1-ETBR coupling in PASMCs triggers PA
vasoconstriction through activation of phospholipase C, which increases IP3 and
diacylglycerol (DAG), and intracellular Ca2+ levels (Galie et al., 2004). ET-1-ETAR coupling
stimulates proliferation of HPASMCs and HPAECs, which contributes to remodeling of PAs
and causes an increase in PVR (Galie et al., 2004; Ould Amer & Hebert-Chatelain, 2018).
ET-1-ETAR coupling also causes lung fibroblasts to proliferate, which leads to further
increases in PVR (Ould Amer & Hebert-Chatelain, 2018). ET-1-ETBR coupling stimulates the
production of endothelium-derived NO, via endothelial nitric oxide synthetase (eNOS) and
potassium channel activation (Maron et al., 2012). The vasodilatory effects of ET-1-ETBR
coupling becomes attenuated in PH due to the high levels of reactive oxygen species present
within the PAs (Maron et al., 2012).
ET-1 receptor antagonists can either inhibit ETAR specifically or both ETAR and ETBR
(dual antagonists). Ambrisentan is a selective ETAR antagonist, while Bosentan and
Macitentan are dual ET-1R antagonists. PH patients treated with dual ET-1R antagonists
showed significant decreases in PVR as well as an increase in their 6-minute walking distances,
lower mortality rates, and a slowing in disease progression (Dupuis & Hoeper, 2008; Galie et
al., 2004; Ould Amer & Hebert-Chatelain, 2018). However, clinical trials did not find ETAR
antagonists to give better prognoses to PH patients, compared to dual ET-1R antagonists, even
though ETAR antagonists do not affect ETBR (Dupuis & Hoeper, 2008; Galie et al., 2004;
Wilkins et al., 2008).
1.2.3 Phosphodiesterase Inhibitors
Phosphodiesterase type 5 (PDE5) inhibitors, such as Sildenafil, are another treatment
available to PH patients. This class of drugs inhibits PDE5, the main enzyme responsible for
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degrading

cyclic guanosine monophosphate

(cGMP), to

the inactive

guanosine

monophosphate (Wilkins et al., 2008). cGMP, which is generated by NO-sensitive guanylyl
cyclase and transmembrane guanylyl cyclases that are activated by natriuretic peptides, is
responsible for regulating vascular smooth muscle cell proliferation and vascular tone. cGMP
activates cGMP-dependent protein kinase, which phosphorylates myosin phosphatase, which
controls the calcium-dependent phosphorylation of myosin light chain by myosin light chain
kinase, leading to smooth muscle contraction, and the IP3 receptor-associated cGMP kinase
substrate, which inhibits calcium release from the sarcoplasmic reticulum (Krawutschke et al.,
2015; Masuda et al., 2010; Nie et al., 2018). By inhibiting the degradation of cGMP through
PDE5, cGMP levels increase, allowing for smooth muscle relaxation to occur and PVR to
decrease.
1.2.4 Guanylate Cyclase Stimulators
Guanylate cyclase stimulators, such as Riociguat, can also be prescribed to PH patients.
These drugs work to increase cGMP through a different mechanism than PDE5 inhibitors.
Instead of preventing the breakdown of cGMP, guanylate cyclase stimulators enhance the
production of cGMP by enhancing the response of soluble guanylate cyclase (sGC) to
endogenous NO, allowing for the reduction of PVR through mechanisms previously described
(Ghofrani et al., 2017; McLaughlin et al., 2017). Riociguat has a dual mode of action. It
increases the activity of sGC up to 73-fold (direct action) and up to 112-fold when acting in
synergy with NO (Ghofrani et al., 2017). Riociguat has been shown to improve exercise
mobility in PH patients and delay clinical worsening ("Riociguat (Adempas) for pulmonary
hypertension," 2014).
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1.2.5 Prostacyclin Analogues
Prostacyclin I2 (PGI2) analogues, such as Epoprostenol, can be prescribed to PH
patients. PGI2 was first isolated from rabbit and pig aortas and found to relax arterial smooth
muscle cells and since then its analogs have been utilized to treat PH (Pluchart et al., 2017).
PGI2 is a major metabolite of arachidonic acid, produced by endothelial cells, and elicits potent
vasodilatory effects, antiproliferative, and anti-inflammatory effects on vascular smooth
muscle (Pluchart et al., 2017). PGI2 binds to the PGI2 receptor, which is a GPR that activates
Gs-coupled receptors on vascular smooth muscle cells to exert its vasodilatory effects on PAs
through cAMP signaling(Pluchart et al., 2017). PGI2 can also activate the peroxisome
proliferator-activated receptors (PPARs) which contribute to the vasodilatory effects of PGI2
(Pluchart et al., 2017). PPARs activate endothelial NO synthase (eNOS) which promotes
vasodilation through activation of sGC, and controls endothelial cell apoptosis through
numerous pathways (Pluchart et al., 2017). Infusion of PGI2 analogs promotes a decrease in
PVR and PAP while prolonging survival of PH patients (Pluchart et al., 2017).
Epoprostenol is a synthetic and unstable analogue of PGI2 that requires infusion to exert
its effects (Pluchart et al., 2017). When treating a patient with Epoprostenol, PVR decreases
due to vasodilation in the pulmonary arteries by mimicking PGI2 and by inhibiting the actions
of ET-1 (Sitbon & Vonk Noordegraaf, 2017). Clinical trials showed patients treated with
Epoprostenol experienced lowered PVR and increased exercise capacity, while also slowing
the progression of PH (Sitbon & Vonk Noordegraaf, 2017). Epoprostenol is also the only
therapy within the PGI2 analog class to reduce mortality (Coghlan et al., 2019; Ould Amer &
Hebert-Chatelain, 2018).
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Selexipag is unique amongst the PGI2 agonist class as it is a prodrug that is structurally
unique from the PGI2 analogs and therefore more stable, allowing for it to be administered
orally (Simonneau et al., 2012). Selexipag is cleaved and converted to its active form in the
liver (Simonneau et al., 2012). The active metabolite of Selexipag is specific for the PGI2
receptor and is not cross-reactive with other prostaglandin receptors (Simonneau et al., 2012).
Selexipag’s active metabolite was shown to relax rat PAs contracted with ET-1 or
phenylephrine (Coghlan et al., 2019). While Selexipag is not as effective in reducing mortality
as the PGI2 analogs that require infusion, its benefit lies in its oral administration, allowing for
better quality of life for PH patients (Coghlan et al., 2019).
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Drugs used for the treatment of pulmonary hypertension
Drug Class

Examples of Drug

Calcium channel blockers

Amlodipine, Nifedipine, Diltiazem

Endothelin receptor antagonists

Ambrisentan, Bosentan, Macitentan

Phosphodiesterase type 5 inhibitors

Sildenafil, Tadalafil

Guanylate cyclase stimulators

Riociguat

Prostacyclin analogs/agonists

Epoprostenol, Iloprist, Treprostinil,
Selexipag

Table 2. The five classes of drugs used to treat pulmonary hypertension with examples from
each category.
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1.3 Hypoxia-induced Pulmonary Hypertension (Group 3 PH)
1.3.1 Hypoxic Pulmonary Vasoconstrictive Response
The lungs have a unique response when exposed to inhaled hypoxia. The PAs in the lungs
contract in response to hypoxic conditions, while the systemic circulation dilates (DunhamSnary et al., 2017). The hypoxic pulmonary vasoconstriction (HPV) response is an intrinsic
reflex contraction of vascular smooth muscle in the PAs in response to a low partial pressure
of oxygen (Lumb & Slinger, 2015) and is theorized to be triggered by a mitochondrial sensor
of low oxygen, which causes a shift in the levels of reactive oxygen species in the PASMCs,
which inhibits potassium channels, depolarizes PASMCs, activates voltage-gated calcium
channels, increases intracellular calcium, and increases Ca2+ sensitivity to the myofilament,
which leads to constriction of the PAs (Dunham-Snary et al., 2017). This reflex occurs within
seconds of hypoxia exposure and consists of two phases. Phase 1 is a brief transient increase
in PAP, which will quickly return to baseline, however, if the hypoxia exposure is prolonged,
phase 2 begins and is a maintained increase in PAP (Lumb & Slinger, 2015) (Figure 1). PAs
contract to divert blood from hypoxic regions of the lungs to regions with more oxygen to
maintain a perfusion-to-ventilation ratio (Dunham-Snary et al., 2017). Persistent hypoxia
eventually leads to the development of PH.
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Figure 1. A graph depicting the hypoxic pulmonary vasoconstriction response in intra-lobar PAs. Created
with BioRender.

11

1.3.2 Chronic Hypoxia Induced PA Constriction and Remodeling
Individuals exposed to chronic hypoxic conditions do not elicit the same HPV response
compared to individuals exposed to acute hypoxia. Chronic exposure to hypoxia can occur
when living in high altitudes or with chronic lung diseases such as COPD, cystic fibrosis,
asthma, and sleep apnea (Stenmark & McMurtry, 2005). Chronic hypoxia exposure leads to
the development of PH, which is caused by PA constriction and remodeling (Figure 2). There
are two structural changes that contribute to the increased PVR seen in chronic hypoxiainduced pulmonary hypertension (HPH), remodeling of the PA wall and a reduction in the
number of small peripheral PAs (aka pruning) (Stenmark & McMurtry, 2005). The PA
remodeling is characterized by increased muscularization and hypertrophy in vessel walls,
causing increased PA resistance (Fagan et al., 2004; Stenmark & McMurtry, 2005; Swenson,
2013).
1.3.2.1 Potential Mechanism of Pulmonary Artery Constriction to Acute and Chronic
Hypoxia
The HPV response elicited by PAs is a reflex contraction of the PASMCs in response
to hypoxia in order to maintain a constant perfusion-to-ventilation ratio in the lungs (DunhamSnary et al., 2017; Lumb & Slinger, 2015). The oxygen sensing capabilities of the pulmonary
system is multifactorial, as mitochondria, carbon dioxide and pH, K+ channel modulation,
hypoxia-inducible factor (HIF), and the cellular energy state can all contribute to oxygen
sensing. Mitochondria are postulated to assist with oxygen sensing through their electron
transport chain (Dunham-Snary et al., 2017). Hypoxia exposure increases the electron transport
chain’s production of reactive oxygen species, which ultimately become hydrogen peroxide
via superoxide dismutase 2, a redox mediator, which alters redox-sensitive ion channels and
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enzymes (Dunham-Snary et al., 2017). Hypoxia also causes lower oxygen levels within the
blood, resulting in a high concentration of H+ in the blood, causing PA vasoconstriction (Lumb
& Slinger, 2015). K+ channel modulation within the PASMCs is also hypothesized to be used
for oxygen sensing. Oxygen can bind reversibly to the sulfur-containing proteins within the
channel, altering their function, and therefore when oxygen content is low, so is the amount of
K+ channel function (Lumb & Slinger, 2015). Another potential oxygen sensor within the
pulmonary circulation is HIF, which is an enzyme that initiates transcription of hypoxiainduced genes (Lumb & Slinger, 2015). When in a hypoxic environment, HIF has a long halflife due decreased oxygen content, which limits the function of prolyl hydroxylase, which is a
key factor in the breakdown of the HIF enzyme (Andrew B. Lumb, 2015). Lastly, cellular
energy state can also contribute to the oxygen sensing capabilities of the pulmonary system.
Hypoxia enhances glycolysis within the PASMCs, which leads to the production of low energy
molecules such as adenosine monophosphate, which activate the enzyme adenosine
monophosphate-activated kinase, which acts to decrease ATP consumption and may release
Ca2+ from the sarcoplasmic reticulum, increasing the intracellular Ca2+ concentration and
causing PA contraction (Lumb & Slinger, 2015). Upon exposure to hypoxic conditions, the
PAs will elicit an HPV response.
The HPV response within the PAs consists of two phases, a potent and transient
increase in PA contraction followed by sustained PA contraction. The first phase of the HPV
response is due to the increase in intracellular Ca2+ in PASMCs triggered by voltage-dependent
and voltage independent Ca2+ entry and release of Ca2+ from intracellular stores, such as the
sarcoplasmic reticulum (Dumas et al., 1999; Dunham-Snary et al., 2017; Ward & McMurtry,
2009). The second phase of the HPV response, which consists of a sustained contraction of
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PAs, is dependent on the sensitization of the PAs to Ca2+ through Rho-kinase (ROCK)
mediated signaling (Ward & McMurtry, 2009). ROCK activation inhibits myosin light chain
phosphatase by phosphorylating the myosin-binding subunit, increasing the amount of
phosphorylation of myosin light chain, which augments PA contractility (Fagan et al., 2004).
While acute exposures to hypoxia are not deleterious, chronic hypoxia exposure leads to
sustained PA constriction and remodeling and increased PAP, thereby leading to PH.
1.3.2.2 Pulmonary Artery Remodeling
PA remodeling is in part, due to ROCK signaling, which regulates actin
polymerization, gene transcription, differentiation, growth, migration, and contraction through
inactivation of myosin light-chain phosphorylation (Fagan et al., 2004; Stenmark & McMurtry,
2005) . ROCK activation also causes a reduction of eNOS within the PA endothelial cells
(PAECs) (Fagan et al., 2004). eNOS is a key factor in the production of NO within pulmonary
vasculature, which allows for vasodilation through the activation of guanylate cyclase. When
eNOS levels are reduced because of ROCK activation, less NO is produced, meaning the
vasoconstrictive effects elicited by hypoxia are not offset through guanylate cyclase activation.
PASMC growth and hypertrophy, which are present with prolonged hypoxia exposure, are also
regulated by ROCK signaling (Fagan et al., 2004). PASMCs also undergo phenotypic
switching, where they shift from a contractile to synthetic phenotype, meaning the PASMCs
have decreased contractile protein expression and increased elastolytic enzymes such as matric
metalloproteinases, ultimately increasing PA stiffness (Pappalardo et al., 2017). The increase
in PASMC growth and hypertrophy is a major cause of PA remodeling, which increases PVR,
ultimately leading to the development of PH.
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Another form of PA remodeling is the pruning of small peripheral PAs, which leads to
an increase in resistance because it decreases the number of parallel vascular pathways
(Stenmark & McMurtry, 2005). Reducing the number of parallel vascular pathways in the
pulmonary vasculature, causes a further increase in PVR. Another cause of PA remodeling is
chronic inflammation, which is present in PH.
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Figure 2. A depiction of the pulmonary artery response when exposed to normoxic, acute hypoxic, and
chronic hypoxic conditions. Created with Biorender.
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1.4 Inflammation and Chemokines/Cytokines
PH is a multifactorial disease that is caused by vasoconstriction, which is caused by
increased intracellular calcium signaling and inflammation of vasculature within in the lungs
and decreased second messenger (cGMP and cAMP) levels, as well as chronic inflammation.
There are two main theories on how inflammation begins in PH: Inside-out theory and
Outside-in theory. In Inside-out theory, chemokines form a gradient on the apical side of
endothelial cells, which provides an environment ideal for inflammatory cell recruitment and
invasion in blood vessels. In contrast, Outside-in theory suggests immune and inflammatory
macrophages accumulate in the adventitia and produce chemokines leading to inflammation
(Lakhkar et al., 2016).
Inflammation can be caused by T- and B-lymphocytes and macrophage infiltration,
which upon binding to inflammatory markers such as interleukin-1β (IL-1β), interleukin-6 (IL6), tumor necrosis factor-α (TNF-α), and various other cytokines, release chemokines
(Alexander et al., 2019; Bordenave et al., 2020; Mamazhakypov et al., 2021). Chemokines,
also known as chemotactic cytokines, are primarily, except for CXCL16 and CX3CL1, small
soluble proteins that regulate immune cell recruitment and functions (Chen et al., 2018; Lumb
& Slinger, 2015). Chemokines can bind to a wide variety of receptors, most of which are
classified as G-protein-coupled receptors (GPR), which have different subgroups such as Gq,
Gs, and Gi (Alexander et al., 2019; Amsellem et al., 2017). While there are almost 800 GPRs,
many of them remain orphan receptors, of which their ligand is unknown (Alexander et al.,
2019).
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1.5 G-protein Coupled Receptors
GPRs are one of the most abundant protein families in humans and are what 30-40%
of pharmaceuticals target (Ahmad & Dalziel, 2020). All GPRs contain a characteristic seven
transmembrane helices that span the intracellular, transmembrane, and extracellular domains
seen in this receptor family (Atanes et al., 2021). The primary function of these receptors is
the transduction of extracellular stimuli into intracellular signals through second messengers
such as cyclic adenosine monophosphate (cAMP) or inositol triphosphate (IP3). Upon binding
to its ligand, an intracellular change occurs on the receptor’s heterotrimeric G protein, where
the guanosine diphosphate (GDP) alpha subunit becomes activated to guanosine triphosphate
(GTP) and separates from the receptor and the other beta and gamma subunits of the
heterotrimer. Next, the heterotrimer is broken into two portions, the alpha and beta-gamma
subunits (Moreira, 2014). GPRs are classified as Gq, Gi, or Gs based on their downstream
pathways. Gq receptors stimulate adenylate cyclase (AC), which produces cAMP. cAMP
activates protein kinase A (PKA), leading to an increase in protein phosphorylation (Mizuno
& Itoh, 2009). Gi signaling inhibit AC and prevent the formation of cAMP (Moreira, 2014).
Gs signaling initiates phospholipase C activity, cleaving phosphatidylinositol to IP3 and
diacylglycerol (DAG), which promote the release of Ca2+ from intracellular stores and
activates Ca2+-binding proteins (Mizuno & Itoh, 2009). One GPR that is gaining a lot of
attention recently is G protein coupled receptor 75 (GPR75).
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Figure 3. Depiction of the three classes of G-coupled protein receptors: Gs, Gq, Gi. Created with BioRender.
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1.6 G-protein Coupled Receptor 75
GPR75 is a 540 amino acid orphan G-protein-coupled receptor that is expressed in
many human tissues such as the brain, lungs, and endocrine tissues (Akbari et al., 2021; Uhlen
et al., 2015). While not much is known about GPR75’s mechanism of function, it may play an
important role in the development of diseases, such as macular degeneration, diabetes, obesity,
and potentially PH (McDonald, 2013; Mizuno & Itoh, 2009; Pappalardo et al., 2017; Sauer et
al., 2001). Recent studies have demonstrated a link between PH and GPR75 using PASMCs
derived from patients diagnosed with idiopathic PH (iPAH) and secondary PAH, in which the
PASMCs had a higher expression level of GPR75 compared to control groups (Iyinikkel, 2019;
McDonald, 2013). These studies show GPR75 is elevated in PH patient pulmonary vessels,
especially in females (Iyinikkel, 2019; McDonald, 2013). While groups agree that GPR75 is a
contributing factor in the development of the previously mentioned diseases, the classification
of GPR based on the second messenger signaling is debated. Some studies indicate GPR75 as
a Gq receptor which utilizes the second messengers DAG and IP3 (Ignatov et al., 2006; Sumin
Lu, 2021), while others suggest it is maybe a Gi-coupled receptor which reduces cAMP
(Iyinikkel, 2019; McDonald, 2013). As mentioned before, GPR75 is classified as an orphan
receptor, indicating that its endogenous ligand remains unknown. While its ligand remains
unknown, there are two contenders that are documented: 20 Hydroxyeicosatetraenoic acid (20HETE) and chemokine ligand 5 (CCL5) (Garcia et al., 2017; Ignatov et al., 2006; Paul et al.,
1999).
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1.7 Ligands of GPR75
1.7.1 20-HETE
20-HETE is an eicosanoid derived from the metabolism of arachidonic acid, by the
cytochrome P450 4A and 4F isozymes, which are present in many tissues including endothelial
cells and vascular smooth muscle cells (Garcia et al., 2017; Mizuno & Itoh, 2009). 20-HETE,
an autocrine and paracrine mediator of cellular processes, has been identified as a contributor
to many disease states, such as hypertension, ischemic and hemorrhagic strokes, acute renal
failure, vascular restenosis, cardiac hypertrophy, myocardial infarction, renal ischemiareperfusion injury, and shock (Roman & Fan, 2018). Endothelial dysfunction is a cause of
hypertension and vascular disease, promoted through 20-HETE uncoupling eNOS and
increasing formation of reactive oxygen species (Roman & Fan, 2018). 20-HETE has been
shown to bind to GPR75 and activates a Gq-signaling in endothelial cells and SMCs (Garcia
et al., 2017; Pascale et al., 2021). 20-HETE contributes to systemic hypertension by sensitizing
vessels to phenylephrine, increased oxidative stress, and endothelial dysfunction, as well as
activating the renin-angiotensin system through increased expression of angiotensinconverting enzyme, contributing to further vasoconstriction (Roman & Fan, 2018).
However, while 20-HETE is deleterious and stimulates vasoconstriction in the
systemic circulation, previous studies show 20-HETE has conflicting effects within the
pulmonary vasculature.
One study found 20-HETE causes transient contraction of bovine PA rings followed
by dilation and induces a potent vasodilatory response in human and rabbit pulmonary
vasculature (Kizub et al., 2016). 20-HETE was also shown to increase survival of pulmonary
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vascular endothelial cells (PMVECs) which underwent hypoxia reoxygenation injury,
prevented mitochondrial depolarization, and enhanced the antioxidant capacity in PMVECs,
which protected ATP production capacity (Sugumaran et al., 2020). These studies indicate 20HETE is protective in the pulmonary vasculature.
Other studies, however, found 20-HETE to be deleterious within the pulmonary
vasculature. One group found 20-HETE acted as a vasoconstrictor in smaller PAs isolated from
rats by blocking Ca2+-activated K+ channels and inhibiting the formation of the vasodilator NO
(Elshenawy et al., 2017). 20-HETE was also found to promote PASMC proliferation and
reactive oxygen species production in another study (Wang et al., 2020). The findings from
these studies indicate 20-HETE is deleterious in the pulmonary vasculature and can aid in the
pathogenesis of PH.
1.7.2 Chemokine Ligand 5
The other potential ligand for GPR75, CCL5 is a proinflammatory chemokine ligand
that has three different chemokine C-C motif receptors (CCRs): CCR1, CCR3, and CCR5
(Culley et al., 2006; Dorfmuller et al., 2002; Singh et al., 2018). CCR1 and CCR3 are highly
expressed in the lungs after injury or perturbation, but CCR5 expression increased only once
CCL5 levels are increased (Nie et al., 2018). CCL5 has been previously shown to contribute
to the pathogenesis of PH, and CCL5-deficient mice develop less PH (Dorfmuller et al., 2002;
Nie et al., 2018). In the lungs, CCL5 is strongly expressed on the primary cells involved in PH,
vascular endothelial cells, SMCs, T-cells, and macrophages (Nie et al., 2018). Once CCL5
binds to one of its receptors, it recruits monocytes, neutrophils, T cells, and eosinophils,
initiating integrin activation, lipid mediator biosynthesis, and degranulation, all of which are
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proinflammatory (Culley et al., 2006; Remy-Jardin et al., 2021). CCL5 can also induce
endothelin-converting enzyme-1, which cleaves big endothelin to its active form, ET-1, a very
potent vasoconstrictor (Uhlen et al., 2015). However, in CCL5-/- mice, PASMC proliferation
and migration was suppressed, which are key contributors to PH development through PA
remodeling (Nie et al., 2018).
Based on this information, we believe GPR75 has a role in the development of chronic
HPH. Using a novel GPR75 knockdown (GPR75-/-) mouse model we aim to uncover the role
of GPR75 in the development of HPH.
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2 Central Hypothesis: We hypothesize that GPR75 plays a critical role in the development
of HPH and silencing of GPR75 can prevent HPH.
3 Specific Aims:
1. Does GPR75 knockdown reduce hypoxic pulmonary vasoconstriction?
2. Does GPR75 knockdown reduce chronic hypoxia induced PH?
3. Does GPR75 regulate cAMP or IP3 and associated signaling in lungs?
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3.1 Specific Aim 1:
Does GPR75 knockdown reduce hypoxic pulmonary vasoconstriction?
1. Are there changes in the contraction of Gpr75-/- vs WT mice pulmonary arteries
exposed to hypoxia ex vivo?

In PH, pulmonary arteries constrict and remodel in

response to hypoxic conditions and in previously mentioned studies (Lu et al., 2021;
Mamazhakypov et al., 2021), PH patients experienced elevated expression levels of
GPR75, and therefore we hypothesize that GPR75 aids in controlling hypoxic pulmonary
vasoconstriction (HPV), which is a physiological response to maintain the alveolar
ventilation capillary perfusion ratio. However, persistent HPV becomes maladaptive and
evokes HPH. To test this hypothesis, intra-lobar pulmonary arteries (IPAs) were harvested
from BL6/J (WT) and Gpr75-/- mice, both 12 weeks of age, and their vascular reactivity
tested. The vessels were briefly exposed to hypoxia (95% N2 – 5% CO2) that lowered the
oxygen tension in the tissue bath to 40 Torr, and we compared the contractions of the two
groups of mice to see if there is a reduced HPV in the Gpr75-/- mice.
2. Can the HPV be altered by putative GPR75 ligands? CCL5 and 20-HETE are two
putative ligands of GPR75, therefore we tested their effects on HPV response. Briefly,
IPAs from WT and Gpr75-/- mice were pretreated with CCL5 or 20-HETE before exposure
to hypoxia, and the HPV response was determined.
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3.2 Specific Aim 2:
Does GPR75 knockdown reduce chronic HPH?
1. Are Gpr75-/- mice protected from developing HPH? PH can be induced by a variety of
conditions, including chronic hypoxia. In hypoxic conditions, pulmonary arteries constrict
to maintain ventilation-to-perfusion quotient and when exposed to hypoxia for a prolonged
period of time, the vessels begin to remodel, which increases pulmonary blood pressure
and afterload on the right heart. This leads to right heart hypertrophy and failure. If our
hypothesis in Aim 1 is correct and GPR75 does lead to an increase in HPV, then we
hypothesize that Gpr75-/- mice are resistant against the development of chronic HPH. To
test this, we will have four groups of mice: Normoxic and hypoxic WT and Gpr75-/- mice.
We kept mice in normoxic (21% O2) or normobaric hypoxic (10% O2) conditions for 5
weeks. At the end of the 5 weeks, we performed echocardiography and right ventricular
catheterization to establish if they developed HPH (pulmonary arterial blood pressure
>25mmHg and significant right heart hypertrophy).
2. Are genes involved in the pathogenesis of HPH up or down regulated by GPR75
knockdown? Further, to determine whether GPR75 signaling affects the development of
HPH, the expression of genes encoding smooth muscle markers, Myh11 and Cnn1,
inflammatory proteins, Ccl2, Ccl5, Cxcl12, and Prom1, and contractile proteins, Bmpr1a
and Rock2, which are implicated in the pathogenesis of HPH, was measured via qRT-PCR
in RNA from lungs of WT and Gpr75-/- mice exposed to normoxic and hypoxic conditions.
3. Are GPR75 and its ligands up or down regulated in humans with PH? While we are
studying how GPR75 affects HPH in mice, it is also important to test if GPR75 expression
is affected in humans with PH. To study this, blood obtained by Dr. Lanier at Westchester
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Medical Center, from patients with scleroderma-associated and idiopathic PH was utilized.
We will determine the gene expression in leukocytes of these two groups to see if GPR75
is more highly expressed in PH patients than non-PH patients. Doing this will allow us to
test if our study in mice holds the potential to be translational.
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3.3 Specific Aim 3:
Does GPR75 regulate cAMP or IP3 and associated signaling in lungs?
1. Determining the 2nd messenger of GPR75. Since GPR75 is a G-protein-coupled receptor,
it affects second messengers, such as inositol 1,4,5-trisphosphate (IP3) and Cyclic
adenosine monophosphate (cAMP). However, the signaling molecules/pathways are
unclear. While some groups have suggested GPR75 functions as a Gq receptor, with its
signaling associated IP3 signaling (Ignatov et al., 2006), others have suggested GPR75 to
function as a Gi receptor, as overexpression and knockdown respectively decrease and
increase cAMP levels in smooth muscle cells (Lu et al., 2021; Mamazhakypov et al., 2021).
The previously mentioned studies indicate that GPR75 signaling is still controversial. To
determine which of these second messengers (cAMP and IP3) are affected by GPR75, we
utilized enzyme-linked immunosorbent assays (ELISAs) in lungs of WT and Gpr75-/- mice.
2. Determining the 2nd messenger signaling and pulmonary artery function. Wire
myography, an ex vivo approach, was utilized to determine which 2nd messenger is
responsible for regulating GPR75 in PA contraction-relaxation function. IPAs were
isolated from WT and Gpr75-/- mice, pretreated with a PKA agonist and antagonist, and
challenged with vasoconstrictors. Altogether, these experiments will provide insight into
signaling downstream of GPR75.
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4. Materials and Methods:
4.1 Animals
Gpr75-/- mice were originally generated by Dr. Artiom Gruzdev and were housed and
bred in New York Medical College’s Department of Comparative Medicine (DCM).
Littermates and/or C57BL/6 (Taconic Biosciences) were eugenic controls. All procedures were
approved by the New York Medical College Institutional Animal Care and Use Committee.
4.2 Generation of the Gpr75-/- Mouse Model
The Gpr75-/- mice were created through a CRE/LOX system, allowing for the gene of
interest, Gpr75 to be excised nonspecifically, generating a global knockdown model. The
conditional null (“Flox”) Gpr75 locus was generated by CRISPR/Cas9-mediated targeting in
G4 (B6129F1) ES cells. The LoxP sites flank 3133 bp, which contains 184 bp of Intron 1-2,
the single coding exon of Gpr75 (exon 2), the entire 3’ UTR, and 208 bp of 3’ extragenic
sequence (floxed sequence chr11:30,890,805-30,893,937 [GRCm38/mm10]). CAS9 double
stranded breaks were targeted to CAGGAATACGACCTCTCCATNGG (5’) and
CCAAAATCCTATACTAGTAGNGG (3’) using the PX459v2 SgRNA/CAS9/Puro delivery
plasmid, a gift from Feng Zhang (Addgene #62988, PMID: 24157548). Two circular repair
templates, each with 600 bp total homology, were used to insert the LoxP sites. To aid clonal
screening, a unique restriction endonuclease site was inserted with each LoxP site: BamHI (5’
LoxP) and ClaI (3’ LoxP). ES clonal screening was done with high fidelity PCR, followed by
restriction digest, and confirmed by direct sequencing of the PCR amplicon sequencing
verification. PCR Primers: 5’LoxP-Fwd: GTACATTGTGCACCTCTTCACAC; 5’LoxP-Rev:
3’LoxP-Fwd:

CTTCCTGAAGGATGGGTCAAAGA;
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ACCAAGCTGTTACAAATGTGCTG;

3’

LoxP-

Rev:

TTGGTTGCTTAATATGCATGACCC). To confirm that no aberrant recombination has
occurred within the Gpr75 coding exon, the entire targeted locus was PCR amplified and
sequenced using the distal screening primers (5’LoxP-Fwd and 3’ LoxP-Rev). Neither of the
two CAS9 target sequences were predicted to have any genetically linked off-target sites,
therefore the ES clones were not screened for any off-target CAS9-mediated mutations.
Homozygously targeted ES clones were microinjected into wildtype blastocyst for standard
chimeric founder generation. The primary Gpr75 flox allele was maintained as a perpetual
backcross to wildtype C57BL/6J mice. To generate the Gpr75-deficient allele, the Gpr75 flox
allele was crossed to B6 CMV-Cre transgenic mice (Jackson Labs Strain 006054; PMID:
8559668). Cre-mediated recombination/excision of the floxed genomic region was confirmed
by direct amplicon sequencing. Genotyping of the flox and null mouse colonies was done by
Transnetyx using allele-specific primer/probe assays.
4.3 Wire Myography
Wire myography was performed on intralobar pulmonary arteries collected from
Gpr75-/- and WT mice in order to examine pulmonary arterial function in response to hypoxic
conditions as well as various treatments (20-HETE, 20-SOLA, CCL5, CCL5 antibody, KCl,
U46619, cAMP-rp, ZD7288, 8-bromo-cAMP, and ET-1). Animals were sacrificed the day of
surgery so freshly harvested intralobar pulmonary arteries can be used for the experiments.
The vessels are mounted in tissue baths filled with 5mL of 1x Krebs Buffer (NaCl: 6.9g/L KCl:
0.35g/L, KH2PO4: 0.163g/L, MgSO4: 0.144g/L, CaCl2: 0.28g/L, NaHCO3-: 2.1g/L, D-Glucose:
1.98g/L, and EDTA: 0.0011g/L in DI water) in order to provide the tissue with an isotonic
solution similar to what would be in the organism, bubbled with an air mixture (21% O2 -
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5%CO2) that mimics room air, and warmed to 37⁰C. A depiction of the vessel isolation and
mounting are located in Figure 3. After normalization, vessels rest for 60 minutes in normoxia
before undergoing treatment with hypoxia (95%N2 – 5%O2; 40 Torr) and/or drug treatments.
Measurements are taken via the programs Myodaq (Myodaq, Danish Myo Technology) and
LabChart (Dunedin, Otago) and analyzed on GraphPad Prism 8.
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Figure 4. A depiction of the wire myography set up. (A) Either a WT or Gpr75-/- mouse is sacrificed and its lungs
quickly arvested and placed in a Kreb’s buffer solution. Intra-lobar pulmonary arteries are dissected out and placed in a
wire myograph bath filled with Kreb’s buffer solution. (B) The wire myograph bath was connected to the transducer,
warmed to 37⁰C, and bubbled with either a normoxic gas mixture or a 95% N2 – 5% CO2 gas mixture to lower the O2
partial pressure in the bath to 40 Torr. Vessel tensions were measured through MyoDaq and analyzed in LabChart8 and
MyoData.
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4.4 Hypoxia Treatment
Both WT and Gpr75-/- mice were born and allowed to reach 3 months of age before
undergoing echocardiography to determine baseline measurements of the heart and pulmonary
artery. Afterwards, mice were either placed in a normobaric hypoxic chamber that was
connected to a regulator set to 10% O2 or left in an animal bay at normoxic conditions for 5
weeks (Figure 5). After 5 weeks, the mice were removed from their conditions and underwent
echocardiography again to determine end point measurements before undergoing terminal
right heart catheterization and having their organs collected, snap frozen, and stored in -80⁰C
until needed.
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Figure 5. Summary of the timeline followed for the mouse experiments and conditions the mice were kept in.
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4.5 Echocardiography and Right Ventricular Catheterization
Mice were allowed to reach 3 months of age before undergoing echocardiography
under isoflurane anesthesia (4% induction; 2% maintenance) to determine baseline reads for
their heart and lung function using the Vevo 770 imaging system (VisualSonics, Toronto, ON,
Canada), before being placed in normobaric normoxic (21% O2 – 5% CO2) or hypoxic (10%
O2 – 5%CO2) for 5 weeks. At the end of five weeks, mice underwent echocardiography under
anesthesia again (4% induction; 2% maintenance) to determine if they developed PH by
comparing their endpoint measurements to their baselines before they underwent cardiac
catheterization while under anesthesia (4% induction; 2% maintenance). After the
catheterization was completed, the animals were sacrificed and their heart, lungs, and aortas
were collected and snap frozen in liquid nitrogen for later biochemical analysis. Detailed
protocols for the echocardiography and the catheterization are referenced in a previously
published paper by our lab (Joshi et al., 2020). A summary of the group set up and timeline are
outlined in Figure 5.
4.6 Human Blood Samples
Blood samples from healthy individuals and patients that diagnosed with sclerodermaassociated PH or iPAH were generated by Dr. Lanier at Westchester Medical Center. Plasma
was isolated by centrifuging for 15 minutes at 2500 RPM at 4°C. The upper layer containing
plasma was removed and frozen, while the remaining lower layer containing red blood cells
was treated with a red blood cell lysing solution for 30 minutes in the dark. The samples were
once again spun for 15 minutes at 2500 RPM to separate the white blood cells from the lysing
solution. The top layer was removed and discarded while the remaining layer containing white
blood cells was stored at -80°C until needed for analysis through qRT-PCR and ELISA.
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4.7 ELISAs
Three ELISA kits are used during the course of these experiments. A Cyclic Adenosine
Monophosphate (cAMP) ELISA, purchased from Cayman Chemicals (#501040) and the
protocol provided by the company for tissues and plasma was utilized. A DuoSet ELISA kit to
measure Chemokine Ligand 5 (CCL5) levels was purchased from R&D Systems (#DY47805). The protocol provided by R&D Systems was utilized for the measurement of CCL5 in
tissues and plasma. An ELISA kit to measure Mouse inositol 1,3,5 Triphosphate (IP3) was
purchased from MyBioSource (#MBS2515928) and the protocol provided by this company
was used to analyze the content of IP3 in tissues and plasma.
4.8 Histology
Lungs were harvested, perfused with 10% paraformaldehyde (PFA) through the main
IPA via drip, and stored in PFA for a week before being given to the New York Medical
College Histology Core for slicing, mounting, and staining. Tissue sections were cut 7μm thick
and stained with Hematoxylin and eosin (H&E), Elastin, or Trichrome. Images were taken on
a Zeiss microscope (Jena, Germany) and wall thickness and vessel size calculated by
measuring the diameter of outer layers of the vessel and the diameter of the vessel lumen,
respectively, using the measurement tools in the program Zen Blue.
4.9 qRT-PCR
RNA was extracted using the QIAGEN miRNeasy kits, the RNA content and quality
was analyzed in a Tek3 plate in the BioTek plate reader. The RNA was transformed into cDNA
using the Thermofisher SuperScript™ IV VILO™ Master Mix kit (Cat# 11766050) and stored
at -80⁰C until necessary. qRT-PCR was performed using Taqman FAM primers and the
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Taqman fast advanced master mix (Cat#: 4444556), following the protocol recommended by
ThermoFisher. Tuba1a is the control gene for these experiments.
4.10 Statistical analysis
Statistical analysis was performed using GraphPad Prism 8 software. Values are
presented as mean ± standard error (SE). Statistical comparisons of samples were made
between two groups with Student’s t-test and to make comparisons among more than two
groups, two-way ANOVA followed by Sidak’s post hoc test for multiple comparisons was
used. Values of P≤0.05 were considered significant.
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5 Results
5.1 Aim 1: Does GPR75 knockdown reduce hypoxic pulmonary vasoconstriction?
5.1.1 Gpr75-/- mice HPV response is less as compared to WT mice.
IPAs from WT and Gpr75-/- mice were mounted on a wire myograph and pretreated
with 1 μmol/L of phenylephrine and exposed to hypoxia (PO2 = 40 Torr). IPAs from Gpr75-/mice as compared to WT mice contracted less to hypoxia (Gpr75-/-: 0.042±0.01 mN/mm2 N=19
and WT: 0.448±0.049 mN/mm2 N=40) and 2nd phase HPV response of IPAs was less in Gpr75/-

compared to WT mice (Figure 6).
As previously mentioned, GPR75 has two putative ligands, CCL5 and 20-HETE. How

the two putative ligands and their inhibitors affected the WT and Gpr75-/- mouse IPA HPV
response were assessed via wire myography.
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Figure 6: Gpr75-/- mice had a significantly decreased HPV response in comparison to WT mice. The arrow
indicates when the hypoxic gas mixture was added to the bath. Both 1st and 2nd phase of HPV is suppressed in Gpr75-/mice in comparison to WT mice. *P<0.05 vs WT, N=40 in WT group, and N=19 in Gpr75-/- group. Statistical
comparisons of samples were performed with Student’s t-test for comparing the two groups, and two-way ANOVA
followed by Sidak’s post-hoc test was performed to compare different time points.
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5.1.2 Pretreatment with CCL5 elicited a stronger 2nd phase of HPV in WT IPAs
To test if CCL5, a putative ligand of GPR75 alters the HPV response in mouse IPAs,
IPAs were isolate from WT mice and pretreated with CCL5 and CCL5-binding antibodies
before exposure to hypoxia. Pretreatment of WT IPAs with CCL5 augmented 2nd phase of
HPV response (CCL5: 0.465±0.234 mN/mm2; N=4; WT: 0.144±0.037 mN/mm2; N=40;
p<0.05), while pretreatment with functional blocking CCL5 antibodies (CCL5-Ab) had no
effect on HPV response as compared to controls (Figure 7A). Interestingly, while CCL5 altered
the 2nd phase HPV response in WT IPAs, CCL5 did not augment the HPV response of Gpr75/=

IPAs (Figure 7B).
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Figure 7: Pretreatment of WT IPAs with CCL5-Ab before exposure to hypoxia (PO2 = 40 Torr) elicited an effect on
HPV response similar to what was seen with Gpr75-/- mouse IPAs exposed to hypoxia. (A) Pretreatment of WT IPAs
with CCL5 before hypoxia exposure led to an elevated 2nd phase HPV response. (B) Pretreatment of Gpr75-/- mouse IPAs
with CCL5 did not elicit any changes in their HPV response. Statistical comparisons of samples were performed with
Student’s t-test for comparing the two groups, and two-way ANOVA followed by Sidak’s post-hoc test was performed to
compare different time points. WT N=40; CCL5-Ab N=5; CCL5=4; Gpr75-/- N=19; Gpr75-/-+CCL5 N= 6.
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5.1.3 Pretreatment with 20-HETE and 20-HETE inhibitors/antagonists did not alter WT
IPAs HPV response
To test if 20-HETE, the other putative ligand of GPR75, altered the HPV response in
mouse IPAs, IPAs were isolated and pretreated with 20-HETE and 20-HETE
antagonists/inhibitors before exposure to hypoxia. Pretreatment with a low dose of 20-HETE
(10 nM; N=4) did not cause any changes in HPV response and a high dose of 20-HETE (30
Nm; N=5) trended to reduce 1st phase HPV response (20-HETE: 0.092±0.028 mN/mm2 N=5;
WT: 0.448±0.049 mN/mm2 N=40) (Figure 8A). WT IPAs were also pretreated with
antagonists and inhibitors of 20-HETE, 6(Z),15(Z)-hydroxyeicoas-6,15-dienamido-diencoic
acid (AAA: antagonist of 20-HETE; N=4), dibromo-dodecenylmethylsulfimide (DDMS; an
inhibitor of 20-HETE synthesis; N=4), and 3-oxa-20-6 15-HEDE (20-HETE antagonist; N=3).
None of these agents affected the HPV response (Figure 8B).
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Figure 8: Effect of 20-HETE or its inhibitors/antagonists on HPV response. (A) Pretreatment with 20-HETE did not
alter the HPV response of WT mouse IPAs. (B) Pretreatment with AAA, DDMS, nor 3-oxa-20-6, 15-HEDE elicited
changes in WT mouse HPV responses. Statistical comparisons of samples were performed with Student’s t-test for
comparing the two groups, and two-way ANOVA followed by Sidak’s post-hoc test was performed to compare different
time points. WT N=40; 20-HETE 10nM N=4; 20-HETE 30nM N=5; AAA N=4; 3-oxa-20-6, 15-HEDE N=3; DDMS
N=4.
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5.2 Aim 2: Does GPR75 knockdown reduce chronic HPH?
5.2.1 Hypoxic Gpr75-/- mice developed less right ventricular pressure but not PA
remodeling
Upon seeing the differences in the HPV of IPAs of Gpr75-/- and WT mice, we tested
whether Gpr75-/- mice were protected from developing HPH by exposing WT and Gpr75-/mice to normoxic (21% O2) and normobaric hypoxic (10% O2) conditions for five weeks.
Gpr75-/- mice exposed to hypoxic conditions for five weeks developed less HPH and RV
hypertrophy (Figure 9). Right heart catheterization showed there was no significant increase
in right ventricular systolic pressure (RVSP) between the normoxic (24.33±1.20 mmHg; N=3)
and hypoxic (36.53±3/97 mmHg; N=8) Gpr75-/- mice, but the RVSP increased (P<0.05) in
hypoxic (56.63±3.46 mmHg; N=11) WT mice (Figure 9A). Right ventricular diastolic pressure
(RVDP) was significantly lower in Gpr75-/- (2.00±0.0 mmHg; N=3) than WT (3.82±0.38
mmHg; N=11) mice in normoxic conditions (Figure 9B). RVDP did not change for Gpr75-/mice exposed to hypoxia as compared to normoxia (2.00±00 mmHg; N=3), but RVDP
increased significantly after 5 weeks of hypoxia (9.793±0.907 mmHg; N=18) compared to
normoxic (3.818±0.377 mmHg; N=11) WT mice (Figure 9B). Another indicator of HPH is
hypertrophy of the right ventricle (RV), which was measured using Fulton’s Index (mass of
right ventricle/mass of LV and septum). While there was no RV hypertrophy in the hypoxic
Gpr75-/- mice, WT mice in hypoxia (0.3515±0.015; N=5) developed significant RV
hypertrophy compared to the normoxic (0.2233±0.0118; N=5) mice (Figure 9C). These results
reveal that Gpr75-/- mice are protected from developing HPH after exposure to chronic
hypoxia, suggesting GPR75 signaling is critical for the development HPH.
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In HPH, remodeling of distal and proximal PAs occurs, causing them to be
hypertrophic and narrowed, which contributes to increase PA resistance that leads to the higher
RVDP and RVSP seen in patients with PH. Having seen the Gpr75-/- mice were protected from
developing increased RVDP and RVSP, as well as right heart hypertrophy, next we determine
the morphology of the PAs within the lungs harvested from WT and Gpr75-/- mice exposed to
normoxia and hypoxia. Lung sections were stained with H&E, Van Gieson’s Stain (EVG), and
Trichrome-mason. EVG and Trichrome-mason staining revealed remodeling of PAs >100µm
was not different between hypoxia WT and Gpr75-/- groups (Figures 10A and B). However,
morphometric analysis of measuring wall thickness to lumen revealed that both WT and
Gpr75-/- mice exposed to hypoxia developed hypertrophy of 100µm PAs as compared to the
normoxic groups (Figure 11).
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Figure 9. Gpr75-/- prevented the development of HPH. Wild type (WT) and Gpr75 knockout (Gpr75-/-) mice were
exposed to normobaric hypoxia (10% O2) or kept in normoxia (21% O2) for 5 weeks. (A, B) Right ventricular systolic
(RVSP) and diastolic (RVDP) pressure increased in hypoxic WT but not Gpr75-/- mice. (C) Right ventricular
hypertrophy (Fulton’s Index) increased in hypoxic WT but not Gpr75-/- mice. *P<0.05 vs normoxia (Nx) and #P<0.05 vs
wild type (WT), N = 11 in wild-type Nx group, N = 18 in wild-type Hx group, N = 5 in Gpr75-/- group, and N = 8 in
Gpr75-/- Hx group. Statistical comparisons of samples were performed with two-way ANOVA followed by Sidak’s posthoc test.
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Figure 10. WT and Gpr75-/- mice exposed to prolonged hypoxia appear to undergo PA remodeling. Elastin and
Trichrome-mason staining was performed on lungs isolated from WT and Gpr75 -/- normoxia- and hypoxia-treated mice.
Elastin staining indicated that pulmonary arteries (>100µm) had media thickening (hypertrophy) in both WT and Gpr75 -/mice exposed to hypoxia for 5-weeks compared to their normoxic-treated counterparts. Trichrome staining indicated that
both Gpr75-/- and WT mice exposed to hypoxia appeared to have more collagen deposition than WT normoxic mice. N = 11
in wild-type Nx group, N = 18 in wild-type Hx group, N = 5 in Gpr75-/- group, and N = 8 in Gpr75-/- Hx group.
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Figure 11. Both WT and Gpr75-/- experienced vascular remodeling after 5 weeks of hypoxia. (A, B) Pulmonary
arteries less than 100μm in diameter in lung slices derived from WT and Gpr75-/- mice exposed to hypoxia for 5weeks increased in media-to-lumen ratio. *P<0.05 vs normoxia (Nx) and N=6 in wild-type group, and N=4 in
Gpr75-/- group. Statistical comparisons of samples were performed with two-way ANOVA followed by Sidak’s
post-hoc test.
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5.2.2 Gpr75 increases in lungs of WT mice exposed to hypoxia and is it primarily
expressed in the pulmonary arteries
After determining the Gpr75-/- mice were protected from developing HPH, it was
important to examine whether Gpr75 expression changed in the mice exposed to hypoxia.
Gpr75 expression significantly increased in the lungs of WT mice exposed to hypoxia for 5
weeks compared to their normoxia exposed counterparts (Figure 12A). However, as expected,
lung Gpr75 expression did not increase in the Gpr75-/- hypoxic group compared to their
normoxic counterparts (Figure 12A). This indicates that Gpr75 levels increase under hypoxic
conditions in WT mice, potentially contributing to the development of HPH.
Next, to determine if Gpr75-/- expression was within PAs or the surrounding soft
tissues, qRT-PCR was performed on lungs with and without intra-lobar and 2nd order PAs.
Lungs of WT mice with their PAs as compared to PAs removed had significantly more Gpr75
mRNA (Figure 12B). These results indicate that a majority of Gpr75 is expressed in the PAs
of mice.
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Figure 12. Wild-type mice treated with hypoxia had elevated Gpr75 expression. (A) Gpr75 mRNA
expression was elevated in wild-type mice kept in hypoxic conditions for 5-weeks, compared to their normoxic
counterparts. There was no change in Gpr75 mRNA expression in the Gpr75 knockout mice in normoxic and
hypoxic conditions. (B) mRNA Gpr75 expression was measured in isolated lungs of wild-type mice with PAs
then without PAs. *P<0.05 vs normoxia; N= 7 for WT normoxic mice; N= 5 for WT hypoxic mice; N= 7 for
Gpr75-/- normoxic mice, and N=5 for Gpr75-/- hypoxic mice. Statistical comparisons of samples were performed
with Student’s t-test for comparing the two groups, and two-way ANOVA followed by Sidak’s post-hoc test for
comparing the four groups.
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5.2.3 Gpr75-/- mice do not experience expression changes in many of the genes involved in
the pathogenesis of HPH
After realizing the Gpr75-/- mice are protected from developing HPH we wanted to
determine whether the gene expression of proteins that contribute to the pathogenesis of HPH
are altered in the lungs of Gpr75-/- mice.
5.2.3.1 Vascular Smooth Muscle Cell Genes
First, we determined the expression of smooth muscle restricted genes myosin heavy
chain 11 (Myh11) and calponin 1 (Cnn1). While expression of Myh11 expression was not
significantly different between the WT and Gpr75-/- mice, there was a significant increase in
Myh11 expression in the lungs of Gpr75-/- hypoxic mice compared to their normoxic
counterparts (Figure 13A). There were no significant changes in Cnn1 expression between the
normoxic and hypoxic WT and Gpr75-/- mice (Figure 13B).
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Figure 13. Myh11 expression was elevated in Gpr75-/- mice exposed to prolonged hypoxia. (A) Myh11
mRNA expression was measured in the lungs of WT and Gpr75-/- mice exposed to normoxia and hypoxia. A
decreasing trend in Myh11 expression was seen between the Nx and Hx WT groups, but Gpr75-/- mice exposed
to hypoxia had higher Myh11 expression compared to their normoxic counterparts. (B) Cnn1 mRNA expression
was measured in the lungs of WT and Gpr75-/- mice exposed to normoxia and hypoxia. No changes in Cnn1
expression was seen in any of the groups. Statistical comparisons of samples were performed with two-way
ANOVA followed by Sidak’s post-hoc test for comparing the four groups. *P<0.05 compared to Nx, N = 10 for
WT-Nx, N = 8 for WT-Hx, N = 8 Gpr75-/--Nx (Myh11), N = 10 Gpr75-/--Nx (Cnn), and N = 7 for Gpr75-/--Hx.
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5.2.3 Bone Morphogenic Protein Receptor and Rho-kinase 2 Genes
Another set of genes that are typically dysregulated in HPH are the bone morphogenic
protein receptor genes, which aid in the regulation of cellular growth and division.
Consistently, Bmpr1a gene expression decreased in lungs from WT hypoxia mice as compared
to the WT normoxia group but not in the lungs of Gpr75-/- normoxia and hypoxia groups
(Figures 14A).
Rho-kinase 2 (Rock2) gene encodes for ROCK2 protein, which increases the Ca2+
sensitivity to myofilament and enhances VSMC contraction, is increased in HPH and aids in
the thickening of the smooth muscle in PAs (Shimizu et al., 2013). Rock2 expression increased
in the WT hypoxic group compared to their normoxic counterparts, but there was no change
in gene expression found in the Gpr75-/- groups (Figure 14B).
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Figure 14. Bmpr1a and Rock2 gene expression was not altered in Gpr75-/- mice exposed to prolonged
hypoxia. Bmpr1a and Rock2 expression was measured in the lungs of WT and Gpr75-/- mice exposed to
normoxia or hypoxia. (A) Bmpr1a expression decreased and (B) Rock2 expression was elevated in WT mice
exposed to hypoxia as compared to their normoxic counterparts, but no changes were seen between the Gpr75-/groups. *P<0.05 compared to Nx, N = 7 for WT-Nx (Bmpr1a), N = 8 for WT-Nx (Rock2), N = 5 for WT-Hx
(Bmpr1a), N = 5 for WT-Hx (Rock2), N = 7 Gpr75-/--Nx (Bmpr1a), N = 7 Gpr75-/--Nx (Rock2), and N =3 for
Gpr75-/--Hx (Bmpr1a), N = 3 for Gpr75-/--Hx (Rock2) . Statistical comparisons of samples were performed with
two-way ANOVA followed by Sidak’s post-hoc test for comparing the four groups.

54

5.2.3.3 Inflammatory genes
Since inflammation is one of the factors for the pathogenesis of HPH, inflammatory
gene expression was also measured in both the WT and Gpr75-/- mice (Stenmark & McMurtry,
2005). The first group examined consisted of C-C Motif Chemokine Ligand 2 (Ccl2), Ccl5,
and C-X-C Motif Chemokine Ligand 12 (Cxcl12), which are chemokines that aid in
chemotaxis and immune cell activation. Ccl2 expression did not change between the normoxic
and hypoxic WT nor the Gpr75-/- groups. However, Ccl2 expression was lower in the Gpr75/-

normoxic group compared to the WT normoxic group (Figure 15A). Ccl5 and Cxcl12 gene

expression increased in the WT mice exposed to hypoxia as compared to the WT normoxic
mice but no changes were seen within the Gpr75-/- groups (Figure 15B-C). Lastly, Prominin 1
(Prom1), which is expressed on hematopoietic stem cells, which are myeloid cell precursors,
(Foris et al., 2016), expression increased in lungs of hypoxic as compared to normoxic WT
mice but did not increase in the lungs of hypoxic Gpr75-/- mice (Figure 15D). Most of the
inflammatory markers increased in the WT mice exposed to hypoxia, but none increased in the
Gpr75-/- hypoxia-exposed mice, which indicates perhaps Gpr75-/- mice have less inflammation
than the WT mice under hypoxic conditions.
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Figure 15. Inflammatory markers did not change in Gpr75-/- mouse lungs after prolonged hypoxia exposure. (A)
Ccl2 expression did not change between the hypoxic and normoxic WT mice nor the Gpr75-/- mice, but less Ccl2
expression was lower in lungs of Gpr75-/- normoxia mice than the WT normoxic mice. (B,C,D) Ccl5, Cxcl12, and
Prom1 expression was significantly elevated in the lungs of WT mice exposed to hypoxia as compared to normoxia. No
changes were seen in the gene expression levels in the Gpr75-/- mouse groups. *P<0.05 compared to Nx, Ccl2: WT-Nx
N=6; WT-Hx N=3; Gpr75-/--Nx N=8; Gpr75-/--Hx N=3; Ccl5: WT-Nx N=8; WT-Hx N=3; Gpr75-/--Nx N=7; Gpr75-/-Hx N=5; Cxcl12: WT-Nx N=6; WT-Hx N=4; Gpr75-/--Nx N=8; Gpr75-/--Hx N=3; Prom1: WT-Nx N=6; WT-Hx N=5;
Gpr75-/--Nx N=6; Gpr75-/--Hx N=3. Statistical comparisons of samples were performed with two-way ANOVA
followed by Sidak’s post-hoc test for comparing the four groups.
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5.2.4 GPR75 as well as its potential ligand CCL5 increases in leukocytes from pulmonary
arterial hypertension patients
To determine if this study was translational to humans, we measured GPR75 and CCL5
mRNA as well as CCL5 and 20-HETE levels in white blood cells (WBC) and plasma,
respectively. WBCs (mononuclear cells) were recently used as surrogates for lungs/PAs to
measure epigenetic enzymes (Potus et al., 2020). Further, bone marrow derived stem cells,
which are precursory for myeloid cells, are upregulated in PAH (Sahara et al., 2007).
Therefore, we used WBC to determine GPR75 and CCL5 mRNA levels. PAH patients,
compared to the control group, have elevated levels of a significant GPR75 in their WBC
compared to the control group, similar to how mice with PH had a significant increase in Gpr75
expression compared to their healthy counterparts (Figures 16A and E). Ccl5 showed an
increasing trend in both mice (Figure 15B) and humans (Figures 16B). Both PH patients and
mice had higher levels of CCL5 in their plasma and lungs respectively (Figure 16C and F).
Levels of 20-HETE, the other proposed ligand to GPR75, was also measured in human plasma
and mouse lungs. Interestingly, 20-HETE levels did not change between the PAH and control
groups in humans, but there was a decrease in 20-HETE levels in the hypoxia exposed mouse
lungs (Figures 16D and G). These results indicate that the study in our mouse model is
translational, as humans experience similar trends in GPR75 gene expression, as well as
expression levels and concentrations of the receptor’s putative ligands.
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Figure 16. GPR75 and CCL5 mRNAS and CCL5 protein are increased in pulmonary hypertension. (A-D) mRNA
of GPR75 and CCL5 and CCL5 protein levels are increased, while 20-HETE did not change in white blood cells and
plasma from iPAH patients (N=5; sex: Female) as compared with control individuals (N=5; Sex: Female). (E-G) mRNA
of Gpr75 and CCL5 protein expression are increased, and 20-HETE is decreased in lungs of female wild-type mice
exposed to hypoxia as compared to normoxia. *P<0.05 compared to Nx or iPAH. N=5 in normoxia and hypoxia.
Statistical comparisons of samples were performed with Student’s t-test.

58

5.3 Aim 3: Does GPR75 regulate cAMP or IP3 and associated signaling in lungs?
5.3.1 Determining the 2nd messenger of GPR75 in mouse lungs
After learning that a lack of GPR75 in the PAs lead to a dampened HPV response and
HPH, we set out to determine whether this was a result of the Gpr75-/- mice having less IP3 or
more cAMP present, and if this would alter how the Gpr75-/- mouse PAs reacted to common
vasoconstrictors. The concentration of IP3 and cAMP was determined using an ELISA kit in
lungs of WT and Gpr75-/- mice. Surprisingly, IP3 did not change between the two groups
(Figure 17B), but the Gpr75-/- mice had more cAMP in their lungs compared to the WTs
(Figure 17A). This increase in cAMP when Gpr75 is knocked out, indicates that GPR75
potentially functions as a Gi-coupled receptor within the lungs, allowing for increased
relaxation in the PAs.
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Figure 17. Cyclic Adenosine Monophosphate (cAMP), not Inositol Triphosphate (IP3) was elevated in Gpr75-/mouse lungs. (A, B) Camp, but no IP3, levels were elevated significantly in the normoxic Gpr75-/- mouse lungs
compared to WT lungs. *P<0.05 compared to Nx. IP3: N=8 WT-Nx, N=8 Gpr75-/-, N=9 WT-Hx, N=8 Gpr75-/--Hx.
cAMP: N = 9 WT-Nx, N = 9 WT-Hx, N = 15 Gpr75-/--Nx, and N = 7 Gpr75-/--Hx. Statistical comparisons of
samples were performed with two-way ANOVA followed by Sidak’s post-hoc test for comparing the four groups.
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5.3.2 Determining the 2nd messenger signaling and pulmonary artery function
As there was a higher concentration of cAMP present within the lungs of Gpr75-/- mice,
and as cAMP is a potent vasodilator (Rybalkin et al., 2003), we hypothesized that PAs from
these animals would respond differently than WTs when challenged with various
vasoconstrictors, such as KCl, a membrane depolarizing agent that activates Rho-kinase
signaling in SMCs, U46619, ET-1, and ZD7288. Therefore, to determine force generation by
the IPAs when challenged with KCl, U46619, an agonist for the Thromboxane A2 receptor,
ZD7288, an antagonist of the hyperpolarization activated cation channels (HCN channels), and
ET-1, which is elevated in PH and couples with ETBR in PASMCs triggers PA vasoconstriction
through an increase in intracellular Ca2+ levels (Galie et al., 2004). PAs of Gpr75-/- mice
generated less tension than the PAs of WT mice to KCl, U46619, ZD7288, and ET-1 (Figures
18A-D). Therefore, these results suggested the decrease in contractile response after
challenging with vasoconstrictors is potentially due to the higher levels of cAMP within the
PAs of the Gpr75-/- mice.
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Figure 18. Gpr75-/- mice PAs contracted less than WT PAs when treated with vasoconstrictors. (A, B, C, D)
KCl, U46619, ZD7288, and ET-1 treatment elicited less contraction in Gpr75-/- than in WT IPAs. *P<0.05 compared
to WT. N = 5 for WT KCl, N = 12 for Gpr75-/- KCl, N = 5 for WT U46619, N = 5 for Gpr75-/- U46619, N = 5 for
WT ZD7288, N = 5 for Gpr75-/- ZD7288, N = 6 for WT ET-1, and N = 5 for Gpr75-/- ET-1. Statistical comparisons
of samples were performed with two-way ANOVA followed by Sidak’s post-hoc test.
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Next, to determine if the elevated cAMP concentration in the Gpr75-/- IPAs was
responsible for the blunted contractile response seen with the addition of KCl, U46619,
ZD7288, and ET-1, Gpr75-/- IPAs were pretreated with protein kinase A (PKA) signaling
inhibitor Rp-cAMPs. Pretreatment with Rp-cAMPs caused Gpr75-/- IPAs to elicit stronger
contractions with addition of KCl and ET-1 compared to the untreated IPAs (Fig 19). However,
application of PKA activator 8-Bromo-cAMPs to Gpr75-/- IPAs was refractory or did not
change force generation by ET-1 but increased force generation by KCl (Fig 19). The same
experiment was also performed on WT IPAs, where pretreatment with Rp-cAMPs caused a
rapid increase in force generation with addition of KCl and ET-1 (Fig 20). When WT IPAs
were pretreated with 8-Bromo-cAMPs addition of KCl and ET-1 generated less forced than
the control vessels (Fig 20).
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Figure 19. Gpr75-/- mouse IPAs contracted more strongly in response to KCl and ET-1 addition with PKA inhibition.
(A, B) Pretreatment of Gpr75-/- IPAs with PKA inhibitor, Rp-cAMPs caused the IPAs to contract more in response to KCl
(A) and ET-1 (B). *P<0.05 compared to KCl/ET-1. N = 11 KCl, N = 7 KCl+Rp-cAMPs, N = 5 KCl+8-Br-cAMPs, N = 13
ET-1, N = 6 ET-1+RpcAMPS, and N = 5 ET-1+8-Br-cAMP. Statistical comparisons of samples were performed with
Student’s t-test for comparing the two groups, and two-way ANOVA followed by Sidak’s post-hoc test was performed to
compare different time points.
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Figure 20. WT mouse IPAs contracted more strongly in response to KCl and ET-1 addition with PKA inhibition.
(A, B) Pretreatment of WT IPAs with PKA inhibitor, Rp-cAMPs caused the IPAs to contract more in response to KCl
(A) and ET-1 (B). *P<0.05 compared to KCl/ET-1. N = 8 KCl, N = 5 KCl+Rp-cAMPs, N = 4 KCl+8-Br-cAMPs, N = 8
ET-1, N = 4 ET-1+RpcAMPS, and N = 4 ET-1+8-Br-cAMP. Statistical comparisons of samples were performed with
Student’s t-test for comparing the two groups, and two-way ANOVA followed by Sidak’s post-hoc test was performed
to compare different time points.
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6 Discussion
The results of this study provide the first evidence that GPR75 signaling is an important
contributor in the pathogenesis of HPH in mice as the Gpr75 gene knockdown mitigated HPV
response and HPH.
HPH consists of two components: vasoconstriction and remodeling. However, in
different animal models of PH, such as rats and mice, these two components have varying
importance (Cahill et al., 2012). PH in rats is caused primarily by sustained ROCK2 mediated
vasoconstriction, and PA remodeling, such as narrowing of the vascular lumen, does not occur
(Cahill et al., 2012). In mice, however, ROCK2 mediated vasoconstriction and remodeling,
such as narrowing of the vascular lumen, of PAs contributed equally to the development of PH
(Cahill et al., 2012). Since both vasoconstriction and remodeling are equally important in the
development of PH in mice, it was interesting to see that our Gpr75-/- mice did not develop
PH, as they experience limited vasoconstriction, but still underwent PA remodeling.
IPAs from Gpr75-/- mice did not elicit HPV, a physiological response triggered by low
oxygen levels in order to maintain a perfusion-to-ventilation quotient (Dunham-Snary et al.,
2017). HPV is regularly seen in PAs when exposed to hypoxic conditions, such as at high
altitudes and lung disorders such as chronic obstructive pulmonary disease, interstitial lung
disease, and sleep apnea, nor did they contract strongly in response to challenging with
vasoconstrictors (Dunham-Snary et al., 2017). Hypoxia exposure activates Ca2+ and Rhokinase-dependent signaling pathways to generate a potent vasoconstrictive response (Knock et
al., 2008). In the HPV response, the first phase is associated with a large, but transient,
elevation in intracellular Ca2+ levels while the second phase of the HPV consists of a small
increase in intracellular Ca2+ levels but the vasoconstrictive effect on PAs is enhanced due to
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a Rho-kinase dependent Ca2+ sensitization pathway (Knock et al., 2008). Ca2+ sensitization of
the PAs is due to Rho-kinase inhibiting myosin light-chain phosphatase, leading to an increase
in phosphorylation of myosin light-chain, which causes PA contraction (Knock et al., 2008;
Lumb & Slinger, 2015; Ward, 2006). Since the PAs of the Gpr75-/- mice did not respond when
exposed to hypoxic conditions and did not elicit strong contractions when challenged with
various vasoconstrictors, we suggest that Gpr75 knockdown prevented and reduced
intracellular Ca2+ and Rho-kinase dependent Ca2+ sensitivity to the myofilament, and reduced
contraction of IPAs elicited by hypoxia, KCl, U46619, and ET-1. By retaining a relaxed state
in hypoxic conditions, the PAs do not undergo the homeostatic response of HPV to divert
blood flow in the lungs from low to high oxygenated regions, which when exposed for
prolonged periods of time leads to PA remodeling, leading to elevated PAP and eventually
HPH. Therefore, we suggest GPR75 signaling has a crucial role in pulmonary/respiratory
physiology, especially in the pathogenesis of HPH.
Further, the theory that GPR75 signaling plays an important role in the pathogenesis of
HPH, is supported by our observations that Gpr75 mRNA expression was 3.2-fold higher in
the lungs of WT mice exposed to hypoxia and 2.0-fold higher in PAH patients compared to
control patients. When Gpr75 was knocked out in mice, Gpr75 did not increase, nor did these
mice develop HPH and RV hypertrophy, indicating that GPR75 contributes to the development
and progression of HPH. While the Gpr75-/- mice did not develop HPH, their PAs still
underwent wall thickening when exposed to hypoxia, similar to what is seen in the WT mice
exposed to hypoxia.
Molecules, such as thromboxane A2 and ET-1, increase with hypoxia exposure and
HPH (Christman et al., 1992). Thromboxane A2, upon binding to its receptor, and ET-1, when
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bound to ETAR, both elicit Gq-coupled signaling (Horinouchi et al., 2013; Mamazhakypov et
al., 2021). Activation of these receptors causes an increase in intracellular Ca2+, which
contributes to vasoconstriction and vascular remodeling in PAs (Horinouchi et al., 2013;
Mamazhakypov et al., 2021). The Gpr75-/- mice exposed to hypoxia for 5-weeks did not
develop HPH, but underwent PA remodeling, suggesting Gpr75-/- increased cAMP levels,
antagonized ET-1 and U46619 (thromboxane A2 mimic) mediated contraction, but not
remodeling of the PAs. This indicates Gpr75 expression and activation of downstream
signaling contributes to constriction, but not the remodeling, of the PAs in HPH mice.
Persistent inflammation and increased cytokines/chemokines are major contributors to
the remodeling of PAs in the lungs of those diagnosed with various types of PH. Cytokines
such as IL-1β, IL-18, IL-6, IL-8, IL-13, and TNF-α, are elevated in PH and contribute to SMC
proliferation and PA muscularization and increase vascular reactivity (Groth et al., 2014).
Chemokines, such as CXCl8, CXCL1, CXCL10, CCL2, CCL5, CXCL12, and CX3CL1, are
increased in PH, which promote inflammation and therefore PA remodeling (Mamazhakypov
et al., 2021). As expected, we saw WT mice exposed to hypoxia express higher levels of Ccl5
gene and CCL5 protein within the lungs, compared to their normoxia exposed counterparts.
Other inflammatory markers and cytokines, such as Cxcl12, were expressed more in the lungs
of hypoxia exposed WT mice compared to the WT normoxia exposed mice. However, this
increase in Ccl5 and Cxcl12 was prevented in the Gpr75-/- mice exposed to hypoxia. Ccl2,
another pro-inflammatory cytokine, was decreased in the lungs of Gpr75-/- as compared to WT
mice. Studies have shown PA endothelial cell CCL2 production is elevated in iPAH patients
which contributes to increased monocyte migration (Hu et al., 2020). This reveals the absence
of Gpr75 may reduce chemotaxis within the lungs, preventing the accumulation of immune
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and pro-inflammatory cells within the lungs of mice exposed to hypoxia. This is also evident
by decreased prominin expression, which indicates the myeloid precursor cells, which
accumulate around the PA in hypoxic mice and contribute to PA remodeling (Hashimoto et
al., 2020). The lack of cytokine elevation, including Ccl2 at baseline, can also alter PA
remodeling, more specifically collagen deposition (Van Linthout et al., 2014). The lack of
cytokines, and therefore inflammation, may potentially lead to less collagen deposition around
the Gpr75-/- mouse PAs. Further, Gpr75 knockdown reduced CCL5, which reduced HPV and
PA pressure, but not remodeling. This indicates CCL5 potentially contributed to increase PA
pressure, but not the PA remodeling in the hypoxia exposed animals.
The two putative ligands of GPR75, CCL5 and 20-HETE, can also contribute to the
inflammatory and contractile response seen in the systemic vasculature (Chandra et al., 2016;
Singh et al., 2018). However, in the pulmonary vasculature, CCL5 is pro-inflammatory and
causes contraction of coronary arteries (Dorfmuller et al., 2002; Nakano et al., 2022). During
the wire myography experiments performed on WT mice, addition of CCL5 augmented the 2nd
phase of the HPV response but had no effect on the Gpr75-/- mouse PA’s HPV response. These
results indicate that CCL5 binds to and activates GPR75 signaling (CCL5-GPR75 coupling)
in the pulmonary vasculature and contributes to constriction of PAs which evokes HPV
response, which leads to HPH. Meanwhile, pretreatment of the WT mouse IPAs with 20-HETE
did not elicit a change from the control WT HPV response, which indicates that 20-HETEGPR75 coupling does not play a role in the HPV response. It has been shown in previous
studies using wire myography, that 20-HETE causes transient contraction followed by
prolonged relaxation in bovine PA rings and induces a potent vasodilatory response in human
and rabbit pulmonary vasculature (Kizub et al., 2016). In our studies, we found 20-HETE
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levels decreased within the lungs of WT mice exposed to hypoxia compared to WT mice kept
in normoxic conditions, which potentially indicates that within the mouse pulmonary
vasculature 20-HETE acts as a vasodilator, which would decrease in response to hypoxic
conditions in order to contract the PAs in order to maintain the perfusion-to-ventilation
quotient, worsening HPV and HPH. Consistently, 20-HETE protects the pulmonary
vasculature from hypoxia-reoxygenation, dilates PAs in rabbit lungs, and reduces HPV (Jacobs
et al., 2012; Kizub et al., 2016; Sugumaran et al., 2020). Therefore, we suggest 20-HETEGPR75 coupling is unlikely to play a role in regulation of PA function in mice exposed to
hypoxia.
Our findings also reveal that cAMP levels are higher in the lungs of Gpr75-/- mice in
normoxia compared to WT normoxia exposed mice, but there are no differences in IP3 levels
between the two groups. This was an unexpected result, as previous studies showed GPR75 as
a Gq-coupled receptor in hippocampal cells (Ignatov et al., 2006) and in the systemic
vasculature (Garcia et al., 2017), which would imply by knocking out the receptor, you would
have lower levels of IP3. Since cAMP levels were higher in the Gpr75-/- mice, this suggests
GPR75 potentially elicits Gi-coupled signaling in the lungs. We propose the increase in cAMP
seen in the Gpr75-/- mice due to a lack in Gi-coupled signaling contributed to the dilatory
phenotype seen in the PAs of these mice, therefore preventing the development of HPH. These
observations are consistent with previous studies (Iyinikkel, 2019; McDonald, 2013).
However, it is unclear if any other interaction or crosstalk between GPR75 and other GCPRs
is responsible for increasing cAMP in lung and needs to be further evalulated.
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cAMP-dependent signaling is not only responsible for the contractile functions of blood
vessels, it regulates other pathways including: contraction, cellular proliferation, metabolism,
and gene expression.
Contraction
cAMP, a molecule generated by the activation of adenylate cyclase, is one mediator of
vasodilation. Within SMCs, cAMP binds to and activates protein kinase A (PKA), which
reduces intracellular levels of Ca2+and decreases Ca2+ sensitivity, imparing myosin light chain
phosphorylation, attenuating SMC contraction (Billington et al., 2013). cAMP can also crossactivate protein kinase G (PKG) to a lesser extent, which also causes a decrease in intracellular
levels of Ca2+, reducing smooth muscle contraction (Billington et al., 2013; Rybalkin et al.,
2003). Elevated levels of cAMP also increases the sarco/endoplasmic reticulum Ca2+-ATPase
(SERCA), which is responsible for sequestering Ca2+ in the sarcoplasmic reticulum, and
ultimately decreases intracellular Ca2+ levels (Billington et al., 2013).
Cellular Proliferation
Depending on the cell type, cAMP can induce or inhibit cellular proliferation through
the alteration of the mitogen-activated protein (MAP) kinase or extracellular signal-regulated
kinase (ERK) pathways (Schmitt & Stork, 2001; Schmitt & Stork, 2002). In vascular SMCs
cAMP inhibits cellular proliferation through protein kinase A (PKA) activating Rap1, allowing
for the disruption of Ras/Raf-1 signaling, preventing proliferation (Grader-Beck et al., 2003;
Schmitt & Stork, 2001). Cell cycle progression can also be halted via cAMP as it can cause an
increase in cell-cycle inhibitor proteins p21cip1 and p27kipl while also decreasing the levels of
cyclin D1 and cyclin D3 (Fukumoto et al., 1999).
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Mitochondrial Function
cAMP also contributes to mitochondrial function by altering complex I, IV, and V
activity. Within complex I, subunit NDUFS4, a protein that when deficient can lead to Leighlike syndrome, a peripheral nervous system pathology, requires PKA phosphorylation for it to
function properly (Alexander et al., 2019). Complex IV, also known as cytochrome c oxidase
(COX), relies on cAMP-PKA signaling to function properly as well, since in hypoxia PKA
phosphorylates subunits I, IV-1, and Vb and induces their degradation, ultimately reducing the
ability of COX to perform oxidative phosphorylation (Roman & Fan, 2018). Complex V also
relies on cAMP in order to control ATP synthase. The ATPase inhibitory factor AIF1, which
binds to complex V to inhibit ATP synthesis, is phosphorylated by PKA in hypoxic conditions,
which prevents its binding to complex V, allowing for the promotion of ATP synthesis (Dupuis
& Hoeper, 2008). All the functions of cAMP within the mitochondria counteract the effects of
hypoxia, allowing for the mitochondria to maintain its ability to produce large amounts of ATP
(Figure 20).
Gene Expression
Lastly, cAMP can alter gene expression through cAMP-responsive element binding
protein (CREB), which is seen in the lungs of animals with PH. In our study, the Gpr75-/- mice
with higher levels of cAMP may have increased CREB activity, which activates Myh11 and
Cnn1 transcription (Kovacs et al., 2018; Qiao et al., 2014; Watson et al., 2002). Increased
expression of Myh11, a SMC-restricted gene, perhaps contributed to PA hypertrophy which
was seen in Gpr75-/- mice exposed to hypoxia. This is not unprecedented because Myh11 has
been seen to contribute to media hypertrophy in the previous studies (Qiao et al., 2014). Since
expression of cytokine genes, Cxcl12, Ccl2, and Ccl5, did not increase in lungs of hypoxic
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Gpr75-/- mice, this would mean they most likely were turned off by the higher cAMPCREB/CREM pathway.
PH is a progressive and deadly cardio-pulmonary disease that has no cure at this time.
The drugs available for PH patients are only used to alleviate their symptoms, not actually treat
the disease itself. Even with treatment PH patients still experience a shortened lifespan.
However, based on our findings on GPR75, we propose that an antagonist to this GPCR might
be beneficial in treating HPH. By blocking GPR75 early on in the diagnosis, remodeling would
still occur within the PAs, but the RV would not experience an increased afterload and
hypertrophy. Inhibition of this protein would also allow for relaxation of the PAs and well as
prevention of excessive inflammation, both of which lead to worsening of PH.
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7 Future Directions
These results reveal some possible actions of GPR75 in PH, however, more
experiments need to be performed to further elucidate the signaling pathway of GPR75 in the
pulmonary vasculature.
Experiments should be performed to determine which cell type(s), endothelial cells or
SMCs, expresses GPR75 in the PAs. Immunofluorescent microscopy could be utilized to see
where GPR75 is expressed in PAs, however, there is a lack of readily available GPR75
antibodies, preventing us from performing these experiments. Due to the lack of GPR75
antibodies, in-situ hybridization using RNA sequences for GPR75 would be the best option
available for identifying the cell type(s) that express GPR75 in the PAs. Tissue-specific,
endothelial cell and SMC, GPR75 knockdown animals should also be generated to determine
which cell type plays is most important in the development of HPH.
A time-course experiment would also be ideal to have in future studies in order to
determine when certain genes are up or down regulated during hypoxia exposure. Our results
only show gene expression and protein levels are a 5-week time course of normoxia or hypoxia,
but it would be interesting to see when Myh11 is elevated in the Gpr75-/- mice exposed to
hypoxia or when 20-HETE levels decrease in the lungs of hypoxia exposed mice. These studies
could help elucidate whether the decrease in 20-HETE is a trigger or a response for some of
the gene expression changes seen in the WT mice exposed to hypoxia.
More experiments also need to be performed in order to determine why the Gpr75-/mice had elevated levels of cAMP in their lungs compared to WT mice. As previously
mentioned, there are conflicting theories on the signaling pathway activated through GPR75
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activation. While our results suggest that GPR75 acts as a Gi-coupled receptor in the pulmonary
system, which is supported by some studies (McDonald, 2013), and other studies performed
in other organ systems show GPR75 functions as a Gq-coupled receptor (Ignatov et al., 2006).
Future experiments should examine why GPR75 acts through different signaling pathways in
different organs. These differences could potentially be due to GPR75 interacting with other
receptors in different organ systems, which leads to it appearing to act as a Gi- and Gq-coupled
receptor depending on its location.
The lack of a clear signaling mechanism for GPR75 also raises the question of whether
this receptor affects other signaling pathways that are crucial for PA contraction and relaxation.
For example, generation of NO by NOS is important for PA SMC relaxation, as inhibition of
eNOS with L-NAME can enhance ROCK-mediated constriction which can cause elevation in
RVSP and PVR (Tanaka et al., 2017). While we did not measure NOS activity in the Gpr75-/mice, we did see the HPV response was completely abolished in the PAs, and if NOS was
somehow linked to GPR75 function, then the Gpr75-/- mouse PAs would have experienced an
increased HPV response. This suggests that NOS is not affected in the Gpr75-/- mice.
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8 Conclusion
In conclusion, deletion of Gpr75 prevented the development of HPH in mice and we
theorize this is through cAMP signaling which allows for PAs to remain relaxed, preventing
the increase in PAP, while also preventing increased inflammation in the PAs through the
reduction of CCL5-GPR75 coupling in the lungs under hypoxic conditions.
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Figure 21. Deletion of Gpr75 leads to an increase in cAMP, which activates PKA, preventing the effects of
hypoxia from taking place within the lungs of mice. Activation of PKA allows for vascular relaxation in
PAs, increases mitochondrial activity within the cell, and alters the expression of genes associated with CREB.
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